MOH

Skillful Craftsman Education Technology Limited Announces Collaborative Agreement of Training Foreign Nurses to Meet Registered Nurses Demand in Singapore

Retrieved on: 
Wednesday, August 30, 2023

WUXI, China, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Skillful Craftsman Education Technology Limited ("the Company" or "Skillful Craftsman") (NASDAQ: EDTK), a leading education technology company providing interactive online learning services, is pleased to announce a collaborative agreement between its Singapore subsidiary, Le First Skilland Pte.

Key Points: 
  • WUXI, China, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Skillful Craftsman Education Technology Limited ("the Company" or "Skillful Craftsman") (NASDAQ: EDTK), a leading education technology company providing interactive online learning services, is pleased to announce a collaborative agreement between its Singapore subsidiary, Le First Skilland Pte.
  • ("Parkway College") to provide specialized training for foreign workers seeking healthcare sector employment in Singapore.
  • For experienced registered nurses (RN) from outside Singapore, obtaining RN status in Singapore requires passing the Singapore Nursing Board Registered Nurse (RN) Licensure Exam, which allows candidates two chances to take the exam.
  • Under this agreement, Skilland will utilize Parkway College's PREPARATORY course to offer systematic trainings to overseas nurses interested in seeking employment in Singapore.

Malaysian Genomics Unveils Strategic Advances in Biopharmaceuticals

Retrieved on: 
Tuesday, August 29, 2023

PETALING JAYA, Malaysia, Aug 29, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023.

Key Points: 
  • PETALING JAYA, Malaysia, Aug 29, 2023 - (ACN Newswire) - Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, recorded a revenue of RM2.23 million for the 4th quarter ended 30 June 2023.
  • The Group will continue to implement stringent credit control policy as they move forward with their initiatives, particularly with Rejuvium.
  • For the current year-to-date, MGRC reported a revenue of RM8.36 million, a decrease from RM28.36 million in the previous year.
  • Malaysian Genomics Resource Centre Bhd: 0155 [BURSA: MGRC] [RIC: MGRC:KL] [BBG: MGRC:MK], http://www.mgrc.com.my/
    Copyright 2023 ACN Newswire .

AcroMeta's Laboratory Construction Business Rides on Singapore's Pandemic Readiness Strategy

Retrieved on: 
Tuesday, August 15, 2023

The state-of-the-art project involves the construction of a high containment biosafety laboratory using modular panels for both reliability and durability to withstand long periods of hard usage and repeated commissioning.

Key Points: 
  • The state-of-the-art project involves the construction of a high containment biosafety laboratory using modular panels for both reliability and durability to withstand long periods of hard usage and repeated commissioning.
  • Construction would be carried out in a 'live' building with many existing tenants without affecting their operations.
  • Singapore emerged from the Covid-19 pandemic as one of the countries that scored high marks for its handling of the crisis.
  • The government has implemented the findings of the Covid-19 White Paper published on 8 March 2023 which detailed the 7 lessons to be learned from the pandemic and implemented a pandemic readiness strategy.

Knight Therapeutics Reports Second Quarter 2023 Results

Retrieved on: 
Thursday, August 10, 2023

Gross margin: For the quarter ended June 30, 2023, gross margin, as a percentage of revenues, was 42% in Q2-23 and 51% Q2-22.

Key Points: 
  • Gross margin: For the quarter ended June 30, 2023, gross margin, as a percentage of revenues, was 42% in Q2-23 and 51% Q2-22.
  • Under the terms of the 2023 NCIB, Knight may purchase for cancellation up to 5,999,524 common shares of the Company which represented 10% of its public float as at June 30, 2023.
  • The increase in the financial outlook is primarily due to an improvement in LATAM currencies against the Canadian dollar in the second quarter of 2023.
  • Knight will host a conference call and audio webcast to discuss its second quarter ended June 30, 2023, today at 8:30 am ET.

Amarin And Neopharm Announce Exclusive Commercialization Agreement for VAZKEPA® (Icosapent Ethyl) in Israel

Retrieved on: 
Tuesday, August 8, 2023

DUBLIN, Ireland, BRIDGEWATER, N.J and PETAH TIKVA, ISRAEL, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) and Neopharm Israel announced today that the two companies have entered into an exclusive marketing and commercialization agreement for VAZKEPA® (icosapent ethyl) in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority. VAZKEPA capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid.

Key Points: 
  • VAZKEPA capsules are the first prescription treatment comprised solely of the active ingredient, icosapent ethyl, a highly purified form of eicosapentaenoic acid.
  • "We are excited to announce this agreement with Neopharm, a leading provider of pharmaceutical commercialization in Israel,” said Patrick Holt, President & CEO, Amarin.
  • “Neopharm is well-positioned with its commercial capabilities, as well as its pedigree and experience in cardiology and related disease categories, to enable access to this important medicine for patients in Israel."
  • Amarin will be responsible for supplying finished product to Neopharm at a transfer price paid to Amarin.

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

Retrieved on: 
Monday, July 31, 2023

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
  • Research and development expenses were $50.1 million for the quarter ended June 30, 2023 compared to $51.4 million for the quarter ended June 30, 2022.
  • Selling, general and administrative expenses were $36.4 million for the quarter ended June 30, 2023 compared to $23.8 million for the quarter ended June 30, 2022.
  • Net loss for the second quarter of 2023 was $4.2 million, or $0.02 per share, compared to a net loss of $62.0 million, or $0.24 per share, for the second quarter of 2022.

UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2023

Retrieved on: 
Tuesday, July 25, 2023

Total consolidated 2Q 2023 UTMD worldwide (WW) sales in USD terms were $562 (4.2%) lower than in 2Q 2022.

Key Points: 
  • Total consolidated 2Q 2023 UTMD worldwide (WW) sales in USD terms were $562 (4.2%) lower than in 2Q 2022.
  • In 2Q 2023 compared to 2Q 2022, OUS sales were $250 (+4.5%) higher and U.S. domestic sales were $812 (10.4%) lower.
  • Total consolidated 1H 2023 UTMD WW sales in USD terms were $366 (1.4%) lower than in 1H 2022.
  • OI in 1H 2023 was $8,864 compared to $9,579 in 1H 2022, a decrease of $715 (7.5%), representing a healthy 1H 2023 OI margin of 34.9%.

Saudi Arabia IVD market rose to $605 Million in 2022, finds global diagnostic market research report

Retrieved on: 
Friday, July 21, 2023

ARLINGTON, Va., July 21, 2023 /PRNewswire-PRWeb/ -- The market for in vitro diagnostics (IVDs) in Saudi Arabia, a young country in an aging world, reached an estimated $605 million in 2022, according to 30-Country IVD Market Atlas, a quarterly updated report from leading diagnostic market research firm Kalorama Information.

Key Points: 
  • Saudi Arabia is one of several major in vitro diagnostic markets analyzed in the research report "30-Country IVD Market Atlas (In Vitro Diagnostic Markets for US, China, Germany, UK, Saudi Arabia, India, UAE, France, Vietnam, Turkey and 20 Other Countries)"
    ARLINGTON, Va., July 21, 2023 /PRNewswire-PRWeb/ -- The market for in vitro diagnostics (IVDs) in Saudi Arabia, a young country in an aging world, reached an estimated $605 million in 2022, according to 30-Country IVD Market Atlas , a quarterly updated report from leading diagnostic market research firm Kalorama Information.
  • Saudi Arabia's IVD market is forecast to have a CAGR of 3.8% between 2021 and 2026.
  • In Saudi Arabia, the IVD market is largely made up of imports as domestic manufacturing of diagnostic tests is nearly nonexistent, according to Kalorama.
  • Although Saudi Arabia is home to more than 35 million people, only 3% are 65 years or older.

Ginkgo Bioworks and the Ministry of Health of the Republic of Botswana Announce Pathogen Monitoring Program at Key Ports of Entry

Retrieved on: 
Monday, July 17, 2023

BOSTON and GABORONE, Botswana, July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.

Key Points: 
  • BOSTON and GABORONE, Botswana, July 17, 2023 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, and the Ministry of Health ("MoH") representing the Government of the Republic of Botswana today announced a pathogen monitoring program at key ports of entry to identify new and emerging variants of SARS-CoV-2.
  • The program builds on Ginkgo's previously announced MOU to develop and implement biosecurity capabilities in Botswana, and will also incorporate pathogen monitoring at land borders, at municipal wastewater treatment works, and for livestock in the food system.
  • This program is built upon a shared recognition by Concentric and the Botswana MoH of the importance of international collaboration and cooperation to promote global health security.
  • Effective pathogen monitoring and data sharing capabilities can empower government officials, community leaders, and other stakeholders to make informed public health decisions.

Italy Construction Equipment Rental Market Assessment & Forecast Report 2023-2029 Featuring Key Vendors - Caterpillar, Volvo, Liebherr, Hitachi, Komatsu, Hyundai, JCB, SANY & CNH Industrial - ResearchAndMarkets.com

Retrieved on: 
Friday, July 7, 2023

The "Italy Construction Equipment Rental Market - Strategic Assessment & Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Italy Construction Equipment Rental Market - Strategic Assessment & Forecast 2023-2029" report has been added to ResearchAndMarkets.com's offering.
  • The Italy construction equipment rental market is expected reach a value of $1.677 billion by 2029 from $1.134 billion in 2022, growing at a CAGR of 5.75%
    Prominent vendors in the Italy construction equipment rental market are Caterpillar, Volvo Construction Equipment, Liebherr, Hitachi Construction Machinery, Komatsu, Hyundai Construction Equipment, JCB, SANY & CNH Industrial.
  • The material handling segment of the overall rental construction equipment accounted for the largest Italy construction equipment rental market share in 2022.
  • The construction of various infrastructure and residential projects in the country is expected to drive the demand for renting aerial platforms in the Italy construction equipment rental market.